Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Adrenocortical Carcinoma 1

Interventions

pembrolizumab 6Mitotane 5Cisplatin 5cabozantinib 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Doxorubicin 3sodium thiosulfate 2relacorilant 2cixutumumab 2cemiplimab 2camrelizumab 2apatinib 2Radiotherapy 2Nivolumab 2Ipilimumab 2Etoposide 2Cytoreduction Surgical Procedures 2milademetan 1lenvatinib 1gossypol acetic acid 1dostarlimab 1cabazitaxel 1antineoplaston AS 2-1 1antineoplaston A10 1Vincristine 1Tamoxifen 1Suramin 1Sunitinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adrenocortical Carcinoma × Dichlorodiphenyldichloroethane × Clear all
NCT00778817 2014-04-29

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
20 enrolled 17 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡